Biomanufacturing CDMO improving access to complex medicines
Resilience (legal name National Resilience) is a biomanufacturing contract development and manufacturing organization (CDMO) building end-to-end manufacturing capacity for biologics, cell & gene therapies, and other complex medicines. Founded in 2020 and last priced at $9.4B in early 2023, it operates a network of US and Canadian manufacturing facilities.
Biotech📍 Blue Ash, OHFounded 2020
Current Valuation
$9.4B
as of 2023-Q1
UNICORN
QL Price
$9.4B
0% vs last round
QuantLogix's current estimate for Resilience, published 2026-10-09 — in line with the last disclosed round of $9.4B (2023-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$9.4B
2023-Q1
weight 0.09
How this price has held up
No round has priced for Resilience since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-09 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Resilience, 2026-10-09 (ef0101120d36af8d).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Resilience going public?
No. Resilience has no imminent IPO plans on record. It is still private.
What is Resilience's valuation in 2026?
Resilience is valued at $9.4B as of 2023-Q1, set by its Series D ($625M, Jan 2023). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Resilience has raised $2.1B in total, most recently a Series D of $625M in Jan 2023.
Is Resilience publicly traded — can you buy Resilience stock?
No. Resilience is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Resilience on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Rahul Singhvi
Founded
2020
HQ
Blue Ash, OH
Employees
~2500
Total Raised
$2.1B
Growth
Raised more than $2B since its 2020 founding to build a domestic biomanufacturing network, then reset: it is winding down six manufacturing sites, has cut staff including 120 in North Carolina, and took a $250M bridge to continue as a streamlined CDMO. The $9.4B Series D mark from January 2023 predates all of that.
product-led hiring — 56% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Manufacturing Technician III, Mechanic - DAP (Nights)Manufacturing Technician II - Inspection (Days)Manufacturing Technician IV, Lead - DAP (Nights)Engineering TechnicianProcess Engineer III- Inspection (Relocation Assistance)Manager, Engineering (Relocation Assistance)
Counted from Resilience's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q1. Refreshed quarterly.